Ordering
Available Variants10 mg
CHA.58022-10mg
Price
€79.52
Available – Dispatch in 14 days
50 mg
CHA.58022-50mg
Price
€256.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.58022-10mg | €79.52 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.58022-50mg | €256.80 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H15NO4 |
|---|---|
| CAS Number | 363600-92-4 |
| Molecular Weight | 285.29 |
| UNSPSC Code | 51111800 |
| NACRES | NA.21 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
TLR2-IN-C29, also known by its CAS number 363600-92-4, is a synthetic compound that functions as an inhibitor of Toll-like receptor 2 (TLR2). TLR2 is a member of the Toll-like receptor family, which plays a crucial role in the recognition of pathogen-associated molecular patterns and the activation of innate immune responses. By inhibiting TLR2, TLR2-IN-C29 has the potential to modulate immune responses and may be useful in the treatment of inflammatory and autoimmune diseases. The compounds mechanism of action involves binding to TLR2, thereby preventing the receptors interaction with its ligands and subsequent activation of downstream signaling pathways. This inhibition can lead to a reduction in the production of pro-inflammatory cytokines and other immune mediators, which may contribute to the development of various diseases. Further research is needed to fully explore the therapeutic potential of TLR2-IN-C29.
